Cerebrospinal Fluid Exposure of Efavirenz and Its Major Metabolites When Dosed at 400 mg and 600 mg Once Daily: A Randomized Controlled Trial



Winston, Alan, Amin, Janaki, Clarke, Amanda, Else, Laura, Amara, Alieu ORCID: 0000-0002-1137-2948, Owen, Andrew ORCID: 0000-0002-9819-7651, Barber, Tristan, Jessen, Heiko, Avinghsanon, Anchalee, Chetchotisakd, Ploenchan
et al (show 5 more authors) (2015) Cerebrospinal Fluid Exposure of Efavirenz and Its Major Metabolites When Dosed at 400 mg and 600 mg Once Daily: A Randomized Controlled Trial. CLINICAL INFECTIOUS DISEASES, 60 (7). 1026 - 1032.

[img] Text
Clin Infect Dis.-2015-Winston-1026-32.pdf
Access to this file is embargoed until Unspecified.

Download (0B)
Item Type: Article
Uncontrolled Keywords: efavirenz, pharmacokinetics, pharmacogenomics, CSF, HIV
Subjects: R Medicine > RM Therapeutics. Pharmacology
Depositing User: Symplectic Admin
Date Deposited: 21 May 2015 15:53
Last Modified: 16 Nov 2019 12:10
DOI: 10.1093/cid/ciu976
Related URLs:
URI: http://livrepository.liverpool.ac.uk/id/eprint/2011747
Repository Staff Access